公开(公告)号：US20190322715A1

公开(公告)日：2019-10-24

申请号：US16504126

申请日：2019-07-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Valentina GOLDFINGER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  C12N15/62 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00 ,  C07K14/725 ,  C07K7/06 ,  G01N33/574 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190322703A1

公开(公告)日：2019-10-24

申请号：US16444693

申请日：2019-06-18

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Steffen WALTER ,  Jens FRITSCHE ,  Colette SONG ,  Harpreet SINGH

IPC: C07K7/08 ,  A61K39/00 ,  C07K7/06 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US20190321442A1

公开(公告)日：2019-10-24

申请号：US16502268

申请日：2019-07-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens FRITSCHE ,  Toni WEINSCHENK ,  Steffen WALTER ,  Peter LEWANDROWSKI ,  Harpreet SINGH

IPC: A61K38/17 ,  C07K7/06 ,  A61K39/00 ,  A61P35/00 ,  G01N33/50

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

公开(公告)号：US20190314475A1

公开(公告)日：2019-10-17

申请号：US16415655

申请日：2019-05-17

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C12N15/115 ,  C07K16/28 ,  C07K16/30 ,  C07K7/06 ,  C12N5/0783

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190314473A1

公开(公告)日：2019-10-17

申请号：US16409393

申请日：2019-05-10

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens Fritsche ,  Harpreet Singh ,  Andrea Mahr ,  Martina Ott ,  Claudia Wagner ,  Oliver Schoor

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190307801A1

公开(公告)日：2019-10-10

申请号：US16421111

申请日：2019-05-23

Applicant: Immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Anita WEIBE ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  C07K14/74 ,  C07K16/30 ,  A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190275131A1

公开(公告)日：2019-09-12

申请号：US16385221

申请日：2019-04-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Phillip MUELLER ,  Julia LEIBOLD ,  Valentina GOLDFINGER

IPC: A61K39/00 ,  G01N33/68 ,  G01N33/574 ,  C12Q1/6886 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  C12N15/115 ,  C07K14/725

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190269767A1

公开(公告)日：2019-09-05

申请号：US16212181

申请日：2018-12-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  G16B25/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190241631A1

公开(公告)日：2019-08-08

申请号：US16388925

申请日：2019-04-19

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  C07K14/725 ,  A61P35/00 ,  C12N5/0783 ,  C07K16/30 ,  C12N15/10 ,  G01N33/574 ,  A61K39/00 ,  C12N15/115 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190192567A1

公开(公告)日：2019-06-27

申请号：US16212198

申请日：2018-12-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/00114 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/804 ,  A61K2039/844 ,  A61K2039/86 ,  A61K2039/884 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.